Jiangsu Hengrui Medicine Co., Ltd.

600276

CNE0000014W7

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Hengrui Medicine Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.78 CNY

Average target price

57.45 CNY

Spread / Average Target

+40.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU HENGRUI MEDICINE CO., LTD.	-9.84%	35.74B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.91%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.68%	244B
ROCHE HOLDING AG	+4.91%	234B
NOVARTIS AG	+16.19%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-07-14 EDT			5-day change	1st Jan Change
40.78 ^CNY	-1.19%		+4.00%	-9.84%

07-08	Hengrui Medicine Gets Inspection Clearance from Jiangsu Province's Drug Regulator	MT
07-05	Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug	MT

Hengrui Medicine Gets Inspection Clearance from Jiangsu Province's Drug Regulator	07-08	MT
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug	07-05	MT
CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine	07-03	MT
Voluntary Announcement - CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Co., Ltd Enter into an Exclusive Promotion Agreement of AYVAKIT® (avapritinib tablets) in Mainland China	07-03	CI
Jiangsu Hengrui Medicine Gets US FDA Approval for Anesthetic; Shares Rise 4%	07-03	MT
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic	07-02	DJ
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.	07-01	CI
Hengrui Pharmaceuticals, Subsidiary Get Regulatory Nod to Test Two Drugs	06-17	MT
Hengrui Pharma Units Get China Nod for Clinical Trial of Tumor Drug	06-05	MT
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug	05-29	MT
China Grants Clinical Trial Approval for Anti-Cancer Injections	05-27	MT
Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs	05-22	MT
Hengrui Pharma Misses US FDA Approval for Cancer Injection	05-21	MT
Hengrui Pharmaceuticals' Unit Gets Nod to Trial SHR-1905 Injection	05-21	MT
Hengrui Grants Rights to Bain Capital-Backed Company for Anti-Diabetes Treatment	05-20	MT
Hengrui Pharmaceuticals to Resubmit Marketing Application for Liver Cancer Drug Combination to US FDA	05-20	MT
Hengrui Pharmaceuticals Plans Up to 1.2 Billion Yuan Share Buyback	05-16	MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	05-15	CI
Jiangsu Hengrui Medicine Co., Ltd. announces an Equity Buyback for CNY 1,200 million worth of its shares.	05-15	CI
Hengrui Pharmaceuticals Unit Gets China Clinical Trial Approval for Kidney Medication	05-14	MT
Jiangsu Hengrui Medicine Co., Ltd. authorizes a Buyback Plan.	05-14	CI
Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 14,351,878 shares, representing 0.22% for CNY 634.67 million.	05-13	CI
Hengrui Pharma's Unit Gets Regulatory Nod to Trial HRS-5965 Capsules	05-09	MT
Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	04-26	MT
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-17	CI